Director Dennis Suskind of CME Group Inc sold 748 shares of Class A common stock on February 6, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at $300.00 apiece, producing a total transaction amount of $224,400. After the sale, Suskind directly holds 2,699 shares of the company.
The stock is trading near its 52-week high of $302.79 and has gained almost 26% over the last 12 months. Current valuation metrics show a price-to-earnings ratio of 27.49, with analysis indicating the stock is trading at a relatively high multiple compared with near-term earnings growth. Technical indicators are flagging the share price as being in overbought territory.
CME Group offers a 3.57% dividend yield and has paid dividends for 23 consecutive years. Additional proprietary research notes that eight more exclusive ProTips and a comprehensive analysis are available in the Pro Research Report for this $110.66 billion market cap company.
In corporate results, CME Group reported fourth-quarter and full-year 2025 earnings that exceeded Wall Street estimates. The company posted earnings per share of $2.77, above the $2.75 forecast, while revenue came in at $1.65 billion versus an anticipated $1.64 billion. These results constituted a modest earnings surprise, though market reaction included a slight pre-market decline in the stock price.
Market participants and analysts continue to track CME Group's near-term trajectory closely. The insider sale, combined with the recent earnings beat, heightened valuation and technical readings, offers investors data points to weigh as they assess exposure to exchange operators and related financial-market infrastructure.
What happened - Director Dennis Suskind sold 748 Class A shares on Feb. 6, 2026 at $300.00 per share, receiving $224,400 and retaining direct ownership of 2,699 shares.
Market context - The stock is trading close to a one-year high and has risen nearly 26% over the past year. Valuation metrics show a P/E of 27.49 and technical indicators suggest the shares are overbought. The company yields 3.57% in dividends and has a 23-year streak of payments.
Earnings update - CME reported Q4 and full-year 2025 EPS of $2.77 versus a $2.75 estimate and revenue of $1.65 billion versus $1.64 billion expected, producing a slight positive surprise while the market reaction was muted.